New drug combo targets Hard-to-Treat cancers in early trial
NCT ID NCT05547321
First seen Jan 04, 2026 · Last updated Jun 22, 2026 · Updated 33 times
Summary
This early-stage trial is testing a new drug called OMTX705, which targets a protein found on cancer cells, either alone or combined with immunotherapy drugs (pembrolizumab or tislelizumab). The study involves 150 adults with advanced solid tumors who have no standard treatment options left. The main goal is to check safety and find the best dose, while also looking for any signs that the tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
Clínica Universitaria de Navarra
RECRUITINGPamplona, Navarre, Spain
Contact
-
Hospital 12 Octubre
RECRUITINGMadrid, Madrid, Spain
Contact
-
Hospital Clínico Universitario de Santiago
NOT_YET_RECRUITINGSantiago de Compostela, Galicia, 15706, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital MD Anderson
RECRUITINGMadrid, Madrid, Spain
Contact
-
Hospital Universitari Vall d'Hebron
NOT_YET_RECRUITINGBarcelona, Barcelona, Spain
Contact
-
Hospital Universitario de Donostia
RECRUITINGSan Sebastián, Guipúzcoa, Spain
Contact
-
ICO L'Hospitalet
RECRUITINGL'Hospitalet de Llobregat, Barcelona, Spain
Contact
-
Onkologikoa
RECRUITINGSan Sebastián, Spain
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OMTX705 (an antibody-drug conjugate targeting fibroblast activation protein) and pembrolizumab or tislelizumab (immunotherapy drugs)
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors that have stopped responding to other therapies.
What could go wrong
This is a very early Phase 1 trial focused on safety and dosing, so it is unknown if OMTX705 will effectively shrink tumors. Side effects from the drug or combination with immunotherapy could be significant.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.